newsfilter
← Latest News
GlobeNewswire·

Kronos Bio Reports Recent Business Progress and First-Quarter 2023 Financial Results

Enrollment ongoing in expansion portion of Phase 1/2 KB-0742 study, with initial efficacy data expected in 2H 2023 Phase 1b/2 study of lanraplenib in combination with gilteritinib in FLT3-mutated AML on track to report